BMY · Bristol Myers Squibb Co · Executive Compensation
$63.43
+1.11 (+1.78%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$129.66B
Shares
2.04B
Volume · Nov 13
9.27M
Avg daily vol (3M)
10.87M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Christopher Boerner | Board Chair and Chief Executive Officer | $21,879,919 |
| Samit Hirawat | Former EVP, Chief Medical Officer, Head of Development | $10,334,233 |
| Cristian Massacesi | M.D. EVP, Chief Medical Officer, Head of Development | $10,072,950 |
| Adam Lenkowsky | EVP, Chief Commercialization Officer | $9,340,352 |
| David Elkins | EVP and Chief Financial Officer | $9,177,590 |
| Greg Meyers | EVP, Chief Digital and Technology Officer | $7,181,173 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christopher Boerner | Board Chair and Chief Executive Officer | $18,787,618 |
| David Elkins | EVP and Chief Financial Officer | $8,707,571 |
| Samit Hirawat | EVP, Chief Medical Officer, Head of Development | $8,586,014 |
| Sandra Leung | EVP and General Counsel | $7,011,790 |
| Karin Shanahan | EVP, Global Product Development & Supply | $6,566,581 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Christopher Boerner | Board Chair and Chief Executive Officer | $8,461,833 |
| David Elkins | EVP and Chief Financial Officer | $7,166,300 |
| Samit Hirawat | EVP, Chief Medical Officer, Head of Development | $6,233,627 |
| Sandra Leung | EVP and General Counsel | $5,923,481 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Elkins | EVP and Chief Financial Officer | $7,647,290 |
| Christopher Boerner | Board Chair and Chief Executive Officer | $6,880,220 |
| Sandra Leung | EVP and General Counsel | $6,104,827 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Cristian Massacesi | Executive Vice President, Chief Medical Officer, and Head of Development | Appointed | 2025-07-25 |
| Sandra Leung | Executive Vice President, General Counsel | Retired | 2025-02-18 |
| Michael R. McMullen | member of the Board | Appointed | 2024-06-18 |
| Phil Holzer | Senior Vice President and Controller | Appointed | 2024-02-15 |
| Christopher Boerner | member of the Board | Appointed | 2023-05-04 |
| Christopher Boerner | Chief Executive Officer | Appointed | 2023-05-04 |
| Christopher Boerner | Chief Operating Officer | Appointed | 2023-05-04 |
| Christopher Boerner, Ph.D. | Chief Executive Officer | Appointed | 2023-04-26 |
| Christopher Boerner, Ph.D. | Chief Operating Officer | Appointed | 2023-04-26 |
| Giovanni Caforio, M.D. | Chief Executive Officer | Retired | 2023-04-26 |
| Dr. Rupert Vessey | Executive Vice President, Research and Early Development | Resigned | 2023-01-31 |
Leadership
- Christopher Boerner CEO, COO, Board Member
- Christopher Boerner, Ph.D. CEO, COO, Board Member
- David Elkins CFO
- Sandra Leung General Counsel
- Deepak L. Bhatt, M.D., M.P.H. Board Member
- Derica W. Rice Board Member
- Manuel Hidalgo Medina Board Member
- Michael R. McMullen Board Member
- Paula A. Price Board Member
Key facts
CIK
14272
CUSIP
110122108
13F (30d)
2056 filings
1929 filers
Visit website
Investor relations